GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (STU:45O) » Definitions » Cyclically Adjusted Price-to-FCF

Orgenesis (STU:45O) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Orgenesis Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orgenesis Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Orgenesis's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Cyclically Adjusted Price-to-FCF Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Orgenesis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Orgenesis's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Orgenesis's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Orgenesis's Cyclically Adjusted Price-to-FCF falls into.



Orgenesis Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Orgenesis's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Orgenesis's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.014/129.4194*129.4194
=-0.014

Current CPI (Dec. 2023) = 129.4194.

Orgenesis Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201402 -0.084 99.057 -0.110
201405 -0.068 100.373 -0.088
201408 -0.029 100.352 -0.037
201411 -0.055 99.635 -0.071
201502 -0.122 99.032 -0.159
201505 -0.105 100.333 -0.135
201508 -0.245 100.548 -0.315
201511 -0.229 100.135 -0.296
201602 -0.178 100.040 -0.230
201605 -0.116 101.355 -0.148
201608 -0.130 101.617 -0.166
201611 -0.132 101.829 -0.168
201702 0.015 102.779 0.019
201705 -0.226 103.256 -0.283
201708 -0.149 103.587 -0.186
201711 -0.060 104.072 -0.075
201802 -0.199 105.052 -0.245
201805 -0.444 106.148 -0.541
201808 -0.444 106.383 -0.540
201811 -0.251 106.338 -0.305
201903 -0.315 107.251 -0.380
201906 -0.300 108.070 -0.359
201909 -0.321 108.329 -0.383
201912 -0.488 108.420 -0.583
202003 -0.733 108.902 -0.871
202006 -0.389 108.767 -0.463
202009 -0.396 109.815 -0.467
202012 -1.565 109.897 -1.843
202103 -0.176 111.754 -0.204
202106 -0.426 114.631 -0.481
202109 -0.356 115.734 -0.398
202112 -0.254 117.630 -0.279
202203 -0.136 121.301 -0.145
202206 -0.376 125.017 -0.389
202209 -0.301 125.227 -0.311
202212 -0.599 125.222 -0.619
202303 -0.301 127.348 -0.306
202306 -0.209 128.729 -0.210
202309 -0.048 129.860 -0.048
202312 -0.014 129.419 -0.014

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Orgenesis  (STU:45O) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Orgenesis Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Orgenesis's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis (STU:45O) Business Description

Industry
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Orgenesis (STU:45O) Headlines

No Headlines